5-HT1A receptor full and partial agonists and 5-HT2C (but not 5-HT3) receptor antagonists increase rates of punished responding in rats

Pharmacology, Biochemistry, and Behavior
L Cervo, R Samanin

Abstract

Drugs with different intrinsic activity at 5-HT1A receptors and antagonists at 5-HT2A/2C and 5-HT3 receptors were studied for their ability to increase the rates of punished operant responding in rats. Like chlordiazepoxide (5 and 10 mg/kg) and diazepam (1.25 and 2.5 mg/kg), 0.125 mg/kg 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), a 5-HT1A receptor agonist, and 5 and 10 mg/kg ipsapirone, a partial agonist at these receptors, increased the rates of punished responding, whereas (S)-WAY 100135, a 5-HT1A receptor antagonist, had no effect at doses from 1 to 10 mg/kg. 8-OH-DPAT and ipsapirone, like benzodiazepines, significantly reduced unpunished responding. The 5-HT2A/2C receptor antagonists ritanserin (2 mg/kg), mianserin (8 mg/kg), and mesulergine (0.1 mg/kg) significantly increased the rates of punished responding, whereas 0.5-2 mg/kg ketanserin, that has higher affinity for 5-HT2A than 5-HT2C receptors, had no effect. Antagonists, at 5-HT3 receptors such as ondansetron (0.001-0.1 mg/kg) and tropisetron (0.001-0.1 mg/kg), had no effect on punished or unpunished responding. The results show that agents acting as full or partial agonists at 5-HT1A receptors and blockers of postsynaptic 5-HT2C receptors have anxiolytic-like...Continue Reading

References

Sep 1, 1992·The Journal of Pharmacy and Pharmacology·E PrzegalinskiM Filip
Jan 1, 1992·Neuroscience and Biobehavioral Reviews·J M BarnesS J Cooper
Dec 4, 1990·European Journal of Pharmacology·S E GartsideS Hjorth
Jan 1, 1990·Pharmacology & Therapeutics·G T Pollard, J L Howard
Dec 7, 1989·European Journal of Pharmacology·L J CornfieldA R Martin
Sep 9, 1986·European Journal of Pharmacology·J S Sprouse, G K Aghajanian
Apr 1, 1988·British Journal of Pharmacology·B J JonesM B Tyers
Jun 1, 1988·British Journal of Pharmacology·A ButlerM B Tyers
May 1, 1994·Pharmacology, Biochemistry, and Behavior·D CharrierM H Thiébot
Jul 1, 1993·Trends in Pharmacological Sciences·D Hoyer, H W Boddeke
Nov 1, 1993·International Clinical Psychopharmacology·B Costall
Jun 24, 1993·European Journal of Pharmacology·A FletcherY Reilly
Sep 25, 1995·European Journal of Pharmacology·L Cervo, R Samanin

❮ Previous
Next ❯

Citations

Feb 6, 2003·European Journal of Pharmacology·Stephen P KelleyClyde W Hodge
Jun 18, 2003·European Journal of Pharmacology·Anna WesołowskaEwa Chojnacka-Wójcik
Jan 29, 2000·European Journal of Pharmacology·G KennettS Bromidge
Sep 23, 1997·Pharmacology, Biochemistry, and Behavior·B J Cao, R J Rodgers
Mar 9, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B OlivierW Soudijn
Aug 31, 2010·Behavioural Pharmacology·Carla PisuLuca Pani
Jan 8, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·A ChagraouiM Bourin
Jun 14, 2003·The Journal of Pharmacy and Pharmacology·Anna WesołowskaEwa Chojnacka-Wójcik

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.